Off-Label Uses of Trulance (Plecanatide)
Medically reviewed by Veronica Hackethal | MD, MSc, Harvard University | University of Oxford | Columbia Vagelos College of Physicians and Surgeons on July 27th, 2026.
Published on July 25th, 2026. Updated on July 28th, 2026.
Key takeaways
Trulance (plecanatide) is FDA-approved for chronic idiopathic constipation and IBS-C, but doctors sometimes prescribe it for other digestive conditions.
Off-label use means a medication is prescribed for a purpose not officially approved by the FDA, which is legal and common in medical practice.
Emerging research suggests plecanatide may benefit patients with opioid-induced constipation and certain functional bowel disorders.
Off-label prescribing decisions should always be made with a licensed clinician who can weigh individual risks and benefits.
If you have questions about whether Trulance is right for your condition, a consultation with a qualified provider is the safest next step.
How Trulance Works in the Gut
Plecanatide is a guanylate cyclase-C (GC-C) agonist, meaning it binds to a specific receptor on the surface of intestinal cells. Once activated, this receptor triggers a cascade that increases fluid and electrolyte secretion into the intestinal lumen. The result is softer, easier-to-pass stool and improved gut transit time.
What makes this mechanism particularly interesting for researchers is that the GC-C receptor is present throughout the gastrointestinal tract, not just in the colon. This broad distribution raises the possibility that plecanatide could influence gut function in areas and conditions beyond its currently approved uses. The drug also mimics uroguanylin, a peptide the body naturally produces, which may contribute to a favorable tolerability profile compared to some other agents.
FDA-Approved Uses Versus Off-Label Prescribing
The FDA has approved Trulance for two specific indications in adults: chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Clinical trials demonstrated statistically significant improvements in complete spontaneous bowel movements, stool consistency, and patient-reported symptoms for both conditions.
Off-label prescribing occurs when a physician recommends a medication for a condition, population, or dosage not covered by its official approval. This practice is entirely legal and accounts for a substantial portion of prescriptions written in the United States each year. Clinicians often turn to off-label options when approved therapies have failed, when a patient has specific contraindications, or when emerging evidence supports an alternative application. The decision is always a clinical one, weighing available evidence against individual patient factors.
Conditions Where Plecanatide Is Sometimes Used Off-Label
Several functional gastrointestinal conditions have drawn clinical interest as potential off-label applications for plecanatide. The table below summarizes the most commonly discussed uses, the level of current evidence, and key considerations.
Off-Label Condition |
Level of Evidence |
Key Considerations |
|---|---|---|
Opioid-induced constipation (OIC) |
Limited; small studies and case reports |
FDA-approved OIC options exist; plecanatide may suit patients who cannot tolerate them |
Functional dyspepsia |
Preliminary; mechanistic rationale only |
GC-C receptors in upper GI tract suggest possible benefit; clinical data sparse |
Pediatric functional constipation |
Very limited; adult dosing not transferable |
Safety and dosing in children not established; use with caution |
Narcotic bowel syndrome |
Anecdotal; no controlled trials |
Complex condition requiring multidisciplinary management |
Slow-transit constipation (refractory) |
Small observational data |
May offer benefit when standard agents fail; individual response varies |
It is worth noting that the absence of robust trial data does not mean a treatment is ineffective. It often simply means that large, expensive trials have not yet been conducted for a given indication. Physicians rely on mechanistic plausibility, smaller studies, and clinical experience when making these decisions.
Opioid-Induced Constipation: A Closer Look
Opioid-induced constipation is one of the more frequently discussed off-label applications for plecanatide. Opioids slow gut motility through mu-opioid receptors in the intestinal wall, leading to hard, infrequent stools that can significantly reduce quality of life. Several FDA-approved medications target opioid receptors directly to address this problem, including methylnaltrexone and naloxegol.
However, not every patient tolerates or responds to these receptor-targeted agents. Because plecanatide works through a completely different pathway, the GC-C receptor, it does not interact with opioid receptors and may be a viable option for those who need an alternative approach. Clinical data specific to this population remain limited, and most evidence comes from case reports and small observational studies rather than randomized controlled trials. A prescribing clinician would need to carefully assess whether the potential benefit outweighs uncertainty in any individual case.
What Patients Should Know Before Asking About Off-Label Use
If you are considering asking your provider about Trulance for a condition not listed on its label, there are several practical points to keep in mind.
First, insurance coverage for off-label prescriptions can be unpredictable. Payers may deny coverage when a medication is used outside its approved indications, leaving patients responsible for the full cost. It is worth checking with your insurer before filling a prescription.
Second, the safety profile established in clinical trials applies specifically to the approved indications. While plecanatide's most common side effect, diarrhea, appears manageable in most patients, long-term data in other populations may be less complete. Your provider can help contextualize what is known and unknown.
Third, Trulance carries a contraindication for use in pediatric patients under six years of age due to the risk of serious fluid loss. This restriction applies regardless of whether the use is on-label or off-label.
Doctronic, the first AI legally authorized to practice medicine in Utah, has handled more than 22 million AI consultations and achieves 99.2% treatment plan alignment with board-certified physicians. Platforms like this can help patients prepare informed, specific questions before meeting with a prescribing clinician, making the conversation more productive for everyone involved.
The Broader Picture of GC-C Agonist Research
Plecanatide belongs to a small but growing class of drugs that work through the guanylate cyclase-C pathway. Its close relative, linaclotide (Linzess), shares a similar mechanism and has also been studied for applications beyond its approved label. Research into GC-C agonists is expanding as scientists learn more about the receptor's role in gut inflammation, visceral pain signaling, and even gut-brain communication.
Some preclinical studies have suggested that GC-C activation may have anti-inflammatory properties in the intestinal lining, raising questions about whether drugs in this class could eventually play a role in inflammatory bowel conditions. These findings are early and should not be interpreted as clinical evidence of benefit, but they illustrate why the research community views this receptor as a promising target. As more data emerge, the landscape of both approved and off-label uses for plecanatide may expand meaningfully over the coming years.
Frequently Asked Questions
Trulance is FDA-approved to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) in adults. These approvals are based on clinical trials showing meaningful improvements in stool frequency, consistency, and related symptoms compared to placebo.
Yes, off-label prescribing is legal and widely practiced. Physicians use clinical judgment, available research, and patient history to guide these decisions. That said, off-label uses may carry less robust safety and efficacy data, so open discussion with your provider is important before starting any new regimen.
Some clinicians prescribe plecanatide off-label for opioid-induced constipation, though dedicated FDA-approved options exist for this condition. Early research suggests possible benefit, but large-scale trials specific to this use are limited. A licensed provider can help determine the most appropriate treatment for your situation.
Trulance mimics a naturally occurring peptide called uroguanylin, activating receptors in the gut lining to increase fluid secretion and move stool along. This local mechanism differs from stimulant laxatives or osmotic agents, potentially making it suitable for patients who have not responded well to other approaches.
Doctronic offers free AI consultations and $39 video visits with licensed clinicians, available 24/7 and HIPAA aligned. With over 22 million AI consultations completed, it provides a convenient, trustworthy starting point for discussing whether plecanatide or another treatment option may be appropriate for you.
The Bottom Line
Trulance (plecanatide) has a well-established role in treating chronic idiopathic constipation and IBS-C, but its guanylate cyclase-C agonist mechanism makes it an appealing candidate for other functional bowel conditions. Off-label applications, including possible use in opioid-induced constipation and functional dyspepsia, are being explored with growing clinical interest. Any off-label use should be guided by a licensed clinician familiar with your full medical history. This article is informational and is not a medical diagnosis. Confirm with a licensed clinician, especially for new, worsening, or high-risk symptoms.
Related articles
Get digestive health advice
Chat Now